December 2016
-
Gateway Analytical has added new analytical testing and consulting services for OINDPs, the company has announced. New services include identification and particle size distribution (PSD) analysis of agglomerated materials and assessment of agglomerates’ effect on… Read more . . .
-
The organizers of Drug Delivery to the Lungs (DDL) 23, which will take place December 5-7 at the Edinburgh International Conference Centre in Edinburgh, UK, are preparing to accommodate a record number of attendees. .… Read more . . .
-
An article posted on October 4, 2012 on the BMJ publication Drug and Therapeutics Bulletin article asks, “who needs teaching?” when it comes to inhaler technique. The article points out that an overwhelming number of… Read more . . .
-
MannKind Corporation says that it has completed recruitment of patients for two Phase 3 studies of Afrezza inhaled insulin. One of the studies will assess HbA1c levels in Type 1 diabetes patients using either injected… Read more . . .
-
Malvern Instruments has launched the Morphologi G3-ID particle characterization system, which combines Raman spectroscopy with particle imaging to provide simultaneous identification of particle size, particle shape, and chemical composition. According to the company, the system… Read more . . .
-
OptiNose has announced results of a randomized, single-dose, four-way cross-over PK study demonstrating that 20% less of its intranasal dry powder sumatriptan product delivered into the nose than Imitrex nasal spray resulted in over 60%… Read more . . .
-
Fresenius Kabi has announced the availability of 30 ml vials acetylcysteine inhalation solution, 20%, helping to alleviate a shortage of the product in the US. The company is marketing the inhalation solution in the US… Read more . . .
-
As expected, the European Commission has approved Novartis’s Seebri Breezhaler glycopyrronium bromide DPI for the treatment of COPD. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive recommendation for… Read more . . .
-
MicroDose Therapeutx has completed the Phase 1 clinical program for its inhaled antiviral fusion inhibitor MDT-637 for the treatment of respiratory syncytial virus infection and plans to present data from the three studies at the… Read more . . .
-
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Novartis’s Seebri glycopyrronium bromide inhalation capsules, delivered by the Breezhaler DPI, for the treatment of COPD. The product should be available in Japan by… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland